Olema Pharmaceuticals, Inc.
General ticker "OLMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $450.6M (TTM average)
Olema Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 33.0%.
Estimated limits based on current volatility of 3.8%: low 27.69$, high 29.87$
Factors to consider:
- Total employees count: 96 (+29.7%) as of 2024
- Top business risk factors: No commercial products, Capital raising, Regulatory and compliance, Geopolitical risks, Supply chain disruptions
- Current price 315.4% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.09$, 8.78$]
- 2025-12-31 to 2026-12-31 estimated range: [2.33$, 6.53$]
Financial Metrics affecting the OLMA estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -29.46 <= 0.04
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 90.68 > 64.17
- Positive: Inventory ratio change, % of 0 <= 0
Short-term OLMA quotes
Long-term OLMA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $106.99MM | $104.96MM | $142.26MM |
| Operating Income | $-106.99MM | $-104.96MM | $-142.26MM |
| Non-Operating Income | $2.20MM | $8.31MM | $12.78MM |
| R&D Expense | $82.27MM | $86.14MM | $124.52MM |
| Income(Loss) | $-104.79MM | $-96.66MM | $-129.47MM |
| Profit(Loss)* | $-104.79MM | $-96.66MM | $-129.47MM |
| Stockholders Equity | $197.55MM | $253.90MM | $408.96MM |
| Assets | $215.65MM | $276.94MM | $450.98MM |
| Operating Cash Flow | $-82.06MM | $-83.73MM | $-104.35MM |
| Capital expenditure | $0.36MM | $0.00MM | $0.16MM |
| Investing Cash Flow | $91.48MM | $-4.85MM | $-93.53MM |
| Financing Cash Flow | $0.48MM | $133.41MM | $268.82MM |
| Earnings Per Share** | $-2.62 | $-2.14 | $-2.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.